What if a regenerative therapy could not only halt sudden hearing loss but also help the inner ear repair itself? Dr. Reimar Schlingensiepen, CEO of Berlin-based biotech AudioCure, joins Brian Taylor to discuss AC102, the company’s lead compound now in Phase 2 clinical trials for sudden sensorineural hearing loss. With limited treatment options available today, the drug is being closely watched as a potential breakthrough in hearing healthcare.Dr. Schlingensiepen explains why sudden hearing loss should be treated as a medical emergency, the shortcomings of current steroid-based approaches, and how AC102 works at the cellular level to prevent programmed cell death and restore critical connections in the auditory system. He also highlights the progress of ongoing clinical trials and discusses how AC102 could potentially improve outcomes for patients undergoing cochlear implant surgery by reducing insertion-related trauma.The discussion further touches on broader applications, including recent preclinical findings published in the International Journal of Molecular Sciences. In that study, AC102 nearly eliminated tinnitus symptoms in an animal model of acoustic trauma while supporting repair of damaged synaptic connections in the inner ear. These results point to the potential for regenerative medicine to reshape treatment of auditory disorders that remain poorly served today.Reference for recently published study on AC102:
Learn more about AudioCure and AC102 here: https://www.audiocure.com/Be sure to subscribe to our channel for the latest episodes each week and follow This Week in Hearing on LinkedIn, Instagram and X.
Visit us at: https://hearinghealthmatters.org/thisweek/
